# Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

> **NCT07097935** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 104 (estimated)

## Conditions studied

- Advanced Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** HS-10516 + Lenvatinib

## Key facts

- **NCT ID:** NCT07097935
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2027-07-10
- **Final completion:** 2028-07-10
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07097935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07097935, "Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07097935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*